MedTrace Logo

Study of LW402 Tablets in Moderate to Severe Rheumatoid Arthritis

NCT06800157 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-10-02

No results posted yet for this study

Summary

This Phase IIa study is designed to evaluate the dose-response relationship, efficacy, safety, and tolerability of LW402 tablets administered for 12 weeks in adult patients with active rheumatoid arthritis receiving background methotrexate (MTX) therapy.

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

Drug: LW402

Oral tablets administered BID

DRUG

Other: placebo

Placebo to match LW402 administered BID

DRUG

MTX

Background treatment with MTX once a week

Sponsors & Collaborators

  • Shanghai Longwood Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-27
Primary Completion
2024-05-26
Completion
2024-08-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06800157 on ClinicalTrials.gov